Low methylation levels among HPV-vaccinated women with cervical HSIL 161 7 15. Hernandez-Lopez R, Lorincz AT, TorresIbarra L, Reuter C, Scibior-Bentkowska D, Warman R, et al. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping. Clin Epigenetics 2019; 11(1): 140. 16. Kremer WW, Dick S, Heideman DAM, Steenbergen RDM, Bleeker MCG, Verhoeve HR, et al. Clinical Regression of HighGrade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4/ miR124-2 DNA Methylation (CONCERVE Study). J Clin Oncol 2022; 40(26): 3037-46. 17. Louvanto K, Aro K, Nedjai B, Bützow R, Jakobsson M, Kalliala I, et al. Methylation in Predicting Progression of Untreated Highgrade Cervical Intraepithelial Neoplasia. Clin Infect Dis 2020; 70(12): 2582-90. 18. Hernández-López R, Lorincz A, TorresIbarra L, Reuter C, Scibior-Bentkowska D, Warman R, et al. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping. Clinical Epigenetics 2019; 11(1). 19. Vink FJ, Meijer C, Hesselink AT, Floore AN, Lissenberg-Witte BI, Bonde JH, et al. FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. Clin Infect Dis 2023; 76(3): e827-e34. 20. Lehtinen M, Pimenoff VN, Nedjai B, Louvanto K, Verhoef L, Heideman DAM, et al. Assessing the risk of cervical neoplasia in the post-HPV vaccination era. Int J Cancer 2023; 152(6): 1060-8. 21. Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, et al. Characteristics of a cluster-randomised phase IV human papillomavirus vaccination effectiveness trial. Vaccine 2015; 33(10): 1284-90. 22. Lehtinen M, Soderlund-Strand A, Vanska S, Luostarinen T, Eriksson T, Natunen K, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a communityrandomised clinical trial (I). Int J Cancer 2018; 142(5): 949-58. 23. Lorincz AT, Brentnall AR, ScibiorBentkowska D, Reuter C, Banwait R, Cadman L, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer 2016; 138(11): 2745-51. 24. Lehtinen M, Gray P, Louvanto K, Vänskä S. In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers. Expert Rev Vaccines 2022; 21(6): 735-8. 25. Vänskä S, Luostarinen T, Baussano I, Apter D, Eriksson T, Natunen K, et al. Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied. Journal of Infectious Diseases 2020; 222(6): 948-56. 26. Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, et al. Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. Int J Cancer 2020; 147(2): 440-7. 27. Bonde JH, Sandri MT, Gary DS, Andrews JC. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. J Low Genit Tract Dis 2020; 24(1): 1-13. 28. Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas J, Hernándes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: Systematic review and meta-analysis. 2018. 29. Zhuang H, Hong S, Zheng L, Zhang L, Zhuang X, Wei H, et al. Effects of cervical conisation on pregnancy outcome: a meta-analysis. Journal of Obstetrics and Gynaecology 2019; 39(1): 74-81. 30. McBride E, Marlow LAV, Forster AS, Ridout D, Kitchener H, Patnick J, et al. Anxiety and distress following receipt of results from routine HPV primary testing in cervical
RkJQdWJsaXNoZXIy MjY0ODMw